Innocoll to Report F
Innocoll to Report Fourth Quarter 2015 Financial Results and Host Webcast and Conference Call on March 17, 2016
March 11, 2016 16:30 ET | Innocoll Holdings plc
ATHLONE, Ireland, March 11, 2016 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the "Company"), a global, commercial stage, specialty pharmaceutical company with late stage development programs...
Innocoll AG Appoints
Innocoll AG Appoints Charles Katzer as Head of Manufacturing and Technical Operations
December 17, 2015 08:30 ET | Innocoll Holdings plc
ATHLONE, Ireland, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL) announced that Charles Katzer has been appointed head of Manufacturing and Technical Operations effective immediately....
Innocoll AG Announce
Innocoll AG Announces Plan to Move Corporate Domicile to Ireland
December 09, 2015 16:30 ET | Innocoll Holdings plc
ATHLONE, Ireland, Dec. 09, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL) today announced that its supervisory board has unanimously approved a plan to move the company’s legal domicile from...
Innocoll AG Announce
Innocoll AG Announces Third Quarter 2015 Financial and Operating Results and Corporate Update
November 11, 2015 08:00 ET | Innocoll Holdings plc
ATHLONE, Ireland, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll to Report T
Innocoll to Report Third Quarter 2015 Financial Results and Host Webcast and Conference Call on November 11, 2015
November 04, 2015 16:05 ET | Innocoll Holdings plc
ATHLONE, Ireland, Nov. 04, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of...
Innocoll AG Announce
Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-2 Phase 3 Study for the Treatment of Postoperative Pain
September 16, 2015 08:00 ET | Innocoll Holdings plc
ATHLONE, Ireland, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll AG Announce
Innocoll AG Announces Departure of Chief Medical Officer
September 14, 2015 08:00 ET | Innocoll Holdings plc
ATHLONE, Ireland, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL) announced that James P. Tursi, M.D., will depart Innocoll to pursue another opportunity. Dr. Tursi will remain with...
Innocoll AG Announce
Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-1 Phase 3 Study for the Treatment of Postoperative Pain
September 02, 2015 08:00 ET | Innocoll Holdings plc
ATHLONE, Ireland, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll AG Announce
Innocoll AG Announces Second Quarter 2015 Financial and Operating Results and Updates Late-Stage Product Portfolio Progress
August 14, 2015 08:00 ET | Innocoll Holdings plc
ATHLONE, Ireland, Aug. 14, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll AG Appoints
Innocoll AG Appoints Rich Fante as Chief Commercial Officer and Head of Business Development
August 13, 2015 08:00 ET | Innocoll Holdings plc
ATHLONE, Ireland, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL) announced that Rich Fante has been appointed Chief Commercial Officer and Head of Business Development effective August...